34708-60-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(3-Hydroxy-phenyl)-propionic acid ethyl ester is used as an intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows for the development of new medications with potential therapeutic benefits.
Used in Fragrance Industry:
In the fragrance industry, 3-(3-Hydroxy-phenyl)-propionic acid ethyl ester is used as a scent ingredient in perfumes and personal care products. Its aromatic properties contribute to the creation of unique and appealing fragrances.
Used in Anti-inflammatory Drug Development:
3-(3-Hydroxy-phenyl)-propionic acid ethyl ester is used as an active compound in the development of drugs for the treatment of inflammatory conditions. Its anti-inflammatory properties make it a valuable component in the formulation of medications aimed at reducing inflammation and alleviating related symptoms.

InChI:InChI=1/C11H14O3/c1-2-14-11(13)7-6-9-4-3-5-10(12)8-9/h3-5,8,12H,2,6-7H2,1H3

Upstream product

• 3943-96-2 3-(3-hydroxyphenyl)acrylic acid ethyl ester 
• 96251-92-2 (E)-3-(3-hydroxyphenyl)acrylic acid ethyl ester 
• 64-17-5 ethanol 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 4046-02-0 ethyl 4-hydroxy-3-methoxycinnamate 
• 591-20-8 3-Bromophenol 
• 140-88-5 ethyl acrylate 
• 14755-02-3 3-hydroxycinnamic acid 

Downstream Products

• 75849-10-4 ethyl 3-<3-(benzyloxy)phenyl>propanoate 
• 156005-68-4 3-{3-[3-(4-Acetyl-phenoxy)-propoxy]-phenyl}-propionic acid ethyl ester 
• 156005-47-9 3-<3-(allyloxy)phenyl>propionic acid ethyl ester 
• 156005-38-8 3-[3-(3-Bromo-propoxy)-phenyl]-propionic acid ethyl ester 
• 174813-74-2 ethyl 3-(3-butoxyphenyl)propanoate 
• 116609-01-9 3-(3-ethoxy-phenyl)-propionic acid ethyl ester 
• 1027377-50-9 3-(3-Isobutoxy-phenyl)-propionic acid ethyl ester 
• 156175-93-8 3-[3-(3-Fluoro-propoxy)-phenyl]-propionic acid ethyl ester 
• 1027051-93-9 3-[3-(4,4,4-Trifluoro-butoxy)-phenyl]-propionic acid ethyl ester 
• 156175-97-2 3-(3-sec-Butoxy-phenyl)-propionic acid ethyl ester 
• 156175-82-5 ethyl 3-(3-propoxyphenyl)propanoate 
• 494865-03-1 3-{3-[3,3-bis-(4-bromo-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester 
• 156005-58-2 ethyl <3-hydroxy-2-(2-propenyl)phenyl>propionate 
• 156005-49-1 ethyl (3-hydroxy-2-propylphenyl)propionate 

Relevant academic research and scientific papers

Preparation method of aza compounds

The invention discloses a preparation method of aza compounds N-((5-(3-hydroxyphenyl)-2H-1,2,4-triazole-3-ol)methyl)-N-propyl-1-amine. 3-(3-hydroxyphenyl)ethyl acrylate serves as an initial material, a target product 7 is obtained through reduction, acyla

Chemo- and Regioselective Hydrogenolysis of Diaryl Ether C-O Bonds by a Robust Heterogeneous Ni/C Catalyst: Applications to the Cleavage of Complex Lignin-Related Fragments

We report the chemo- and regioselective hydrogenolysis of the C-O bonds in di-ortho-substituted diaryl ethers under the catalysis of a supported nickel catalyst. The catalyst comprises heterogeneous nickel particles supported on activated carbon and furnishes arenes and phenols in high yields without hydrogenation. The high thermal stability of the embedded metal particles allows C-O bond cleavage to occur in highly substituted diaryl ether units akin to those in lignin. Preliminary mechanistic experiments show that this catalyst undergoes sintering less readily than previously reported catalyst particles that form from a solution of [Ni(cod)2].

COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of kidney and/or liver disease.

Calcilytic compounds

Novel calcilytic compounds and methods of using them are provided.

Benzocarbazoles dioxane derivatives, its preparation process and its use in medicine

The invention relates to a benzodioxane derivative, a preparation method thereof and application of the derivative in medicines. Specifically, the invention relates to a novel benzodioxane derivative shown as a formula (I), medial salt thereof or a medicine composition containing the derivative, and a preparation method of the derivative. The invention further relates to a use of the benzodioxane derivative and the medial salt thereof or the medicine composition containing the derivative in preparing therapeutic agent, especially GPR 40 agonist, and a drug for treating the diseases such as diabetes, metabolic disorders and the like, wherein each substituent group in the formula (I) is as defined in the description.

Development of a practical and scalable synthesis of a potent CRTH2 antagonist

This contribution describes the process research and development of a practical and scalable synthetic method towards compound 1, which has a potent CRTH2 antagonistic activity. The medicinal chemistry synthetic route and second generation synthetic route

POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS

The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

Identification and synthesis of a novel selective partial PPARδ agonist with full efficacy on lipid metabolism in vitro and in vivo

The aim was to identify a novel selective PPARδ agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo. Using the triple PPARα,γ,δ agonist 1 as the structural starting point, we wanted to investigate the

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. (Formula

Calcilytic compounds

Novel calcilytic compounds and methods of using them are provided.